1. Mazzucchelli, Renata, and Scott K. Durum. "Interleukin-7 receptor expression: intelligent design." Nature Reviews Immunology 7.2 (2007): 144-154.
2. Fry, Terry J., and Crystal L. Mackall. "Interleukin-7: from bench to clinic." Blood, The Journal of the American Society of Hematology 99.11 (2002): 3892-3904.
3. Ponchel, Frederique, et al. "Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia." Arthritis Res Ther 7.1 (2004): R80.
4. Seddiki, N. Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. "Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells." J Exp Med 203 (2006): 1693-1700.
Visit our Scientific Publication section for more information on NT-I7 for Oncology
NIT is collaborating with major cancer centers and universities in the U.S. and South Korea for our clinical trials with NT-I7. To learn about our on-going cancer clinical trials, please click Here .
In clinical trials, NT-I7 has demonstrated the ability to increase absolute lymphocyte counts, including naïve and memory CD4+ and CD8+ T cells, and exhibited a well-tolerated safety profile.
1. Guan W, Ni Z, Hu Y et al. “Clinical Characteristics of Coronavirus Disease 2019 in China.” New England Journal of Medicine. 2020;382(18):1708-1720.
2. Huang C, Wang Y, Li X et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.” The Lancet. 2020;395(10223):497-506.
3. Tan L, Wang Q, Zhang D et al. “Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.” Signal Transduct Target Ther. 2020;5(1).
4. Terrazzini N, Mantegani P, Kern F, Fortis C, Mondino A, Caserta S. “Interleukin-7 Unveils Pathogen-Specific T Cells by Enhancing Antigen-Recall Responses.” J Infect Dis. 2018;217(12):1997-2007.
5. Deshpande P, Cavanagh M, Le Saux S, Singh K, Weyand C, Goronzy J. “IL-7– and IL-15–Mediated TCR Sensitization Enables T Cell Responses to Self-Antigens.” The Journal of Immunology. 2013;190(4):1416-1423.
6. Mackall C, Fry T, Gress R. “Harnessing the biology of IL-7 for therapeutic application.” Nature Reviews Immunology. 2011;11(5):330-342.
7. Zheng M, Gao Y, Wang G et al. “Functional exhaustion of antiviral lymphocytes in COVID-19 patients.” Cell Mol Immunol. 2020;17(5):533-535.
8. Zheng H, Zhang M, Yang C et al. “Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.” Cell Mol Immunol. 2020;17(5):541-543.
9. Yang X, Dai T, Zhou X et al. “Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS-CoV-2.” 2020.
NIT is collaborating with major cancer centers and universities for our clinical trials with NT-I7. To learn about our on-going clinical trials in infectious diseases, please click Here .
1. Maintaining homeostasis
- Supports Thymopoiesis
- Boosts Tnaive cell numbers
- Maintains stable pools of diverse resting peripheral T cells, including Tscm
2. Initial Immune Response
- Boosts Tnaive cell numbers and broadens TCR repertoire diversity
- Increases sensitivity to weaker antigens
- Synergizes with TCR signaling
3. Adaptive Immune Response
- Promotes Tmemory differentiation and turnover
- Limits T cell exhaustion
- Sustains immune response to chronic antigen stimulation
Visit our Scientific Publication section for more information on NT-I7 for immunological disorders.
NIT is collaborating with major cancer centers and universities in the U.S. and South Korea for our clinical trials with NT-I7. To learn about our clinical trials for immunological disorders, please click Here .
1. Maintaining homeostasis
- Supports Thymopoiesis
- Boosts Tnaive cell numbers
- Maintains stable pools of diverse resting peripheral T cells, including Tscm
2. Initial Immune Response
- Boosts Tnaive cell numbers and broadens TCR repertoire diversity
- Increases sensitivity to weaker antigens
- Synergizes with TCR signaling
3. Adaptive Immune Response
- Promotes Tmemory differentiation and turnover
- Limits T cell exhaustion
- Sustains immune response to chronic antigen stimulation
Visit our Scientific Publication section for more information on NT-I7 for immunological disorders.
NIT is collaborating with major cancer centers and universities in the U.S. and South Korea for our clinical trials with NT-I7. To learn about our clinical trials for immunological disorders, please click Here .